Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma ...Middle East

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the...

Hence then, the article about final analysis of phase 2 griffin study presented for darzalex daratumumab based investigational quadruplet regimen in patients with newly diagnosed transplant eligible multiple myeloma was published today ( Saturday 27/08/2022 - 11:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma )

Also on site :

• US-Patient mit fortgeschrittenem Lungenkrebs durch neuartige Immuntherapie-Behandlung in China stabilisiert
• Who is Iran’s new supreme leader Mojtaba Khamenei? Son of Ayatollah Ali Khamenei to take over father’s role
• Egypt Proposes Forming Joint Arab Defense Force Amid Regional Tensions